

10-24-05

IF 1642

Please type a plus sign (+) inside this box ☐

☐

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		Application Number	09/403,440
		Filing Date	January 19, 2000
		First Named Inventor	Lane, David Philip
		Group/Art Unit	1642
		Examiner Name	Davis, Minh Tam B.
Total Number of Pages in This Submission		Attorney Docket Number	39749-0001APC

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Version with Markings Showing Changes <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request (3-month EOT = \$1,020.00) <input type="checkbox"/> Information Disclosure Statement and PTO-1449 (with 61 references cited and 51 references submitted) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): stamped return postcard
<b>Remarks</b> AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER. PLEASE REFERENCE ATTORNEY DOCKET NO. 39749-0001 APC.		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT			
Firm or Individual name	GINGER R. DREGER, ESQ., REG. NO. 33,055, HELLER EHRMAN LLP		
Signature			
Date	OCTOBER 21, 2005	Customer Number:	25213

CERTIFICATE OF EXPRESS MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop <u>AMENDMENT</u> , Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date: <b>OCTOBER 21, 2005</b>			
		Express Mail Label	EL 976 550 152 US
Typed or printed name	SANDRA PULJIC		
Signature		Date	OCTOBER 21, 2005

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop \_\_\_\_, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

David Philip LANE

Application Serial No. 09/403,440

Filed: January 19, 2000

For: **MATERIALS AND METHODS  
RELATING TO INHIBITING THE  
INTERACTION OF p53 AND mdm2**

) Examiner: Davis, Minh Tam B.

) Art Unit: 1642

) Attorney's Docket No. 39749-0001APC

) **Customer No. 25213**

---

EXPRESS MAIL LABEL NO. EL 976 550 152 US  
DATE MAILED: OCTOBER 21, 2005

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each publication other than U.S. patents and U.S. patent application publications, and each cited pending unpublished U.S. application along with a concise explanation of information in a foreign language pursuant to 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Form PTO-1449 is enclosed and the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.


10/26/2005 BABRAHA1 00000097 081641 09403440

01 FC:1806 180.00 DA


- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☒ a fee of **\$180.00** as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of **\$180.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39749-0001APC).**

Respectfully submitted,

Dated: October 21, 2005

By:   
Ginger R. Dreger (Reg. No. 33,055)

**HELLER EHRMAN LLP**  
275 Middlefield Road  
Menlo Park, California 94025-3506  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638



OCT 21 2005

Form PTO-1449

Attorney's Docket No.  
39749-0001APCApplication Serial No.  
09/403,440

## INFORMATION DISCLOSURE STATEMENT

Applicant(s)

David Philip Lane

(use several sheets if necessary)

Filing Date:  
January 19, 2000Group Art Unit:  
1642

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.	Nov. 8, 1994	5,362,623	Vogelstein, B., <i>et al.</i>	435/6	435/320	
	2.	May 2, 1995	5,411,860	Vogelstein, B., <i>et al.</i>	435/6	435/91.2	
	3.	May 30, 1995	5,420,263	Burrell, M., <i>et al.</i>	536/23.1	536/23.2	
	4.	May 21, 1996	5,519,118	Vogelstein, B., <i>et al.</i>	530/350	530/388.6	
	5.	Jul. 2, 1996	5,532,348	Huibregtse, J.M., <i>et al.</i>	536/23.5	435/235.1	
	6.	Aug. 27, 1996	5,550,023	Kinzler, K.W., <i>et al.</i>	435/7.1	435/7.2	
	7.	Feb. 25, 1997	5,606,044	Burrell, M., <i>et al.</i>	536/24.31	206/569	
	8.	Apr. 8, 1997	5,618,921	Burrell, M., <i>et al.</i>	530/387.7	530/388.85	
	9.	Dec. 30, 1997	5,702,908	Picksley, S.M., <i>et al.</i>	435/7.8		
	10.	Jun. 23, 1998	5,770,377	Picksley, S.M., <i>et al.</i>	435/7.1	435/7.9	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation	
							YES	NO
	11.	Jan. 6, 1994	WO 94/00601	Levine, A.J., <i>et al.</i> , PCT/US93/06063	C12Q 1/68	G01N 33/574		X
	12.	Apr. 14, 1994	WO 94/08241	Zentgraf, H., <i>et al.</i> , PCT/EP93/02666	G01N 33/574	C07K 11/00		X
	13.	May 11, 1994	WO 94/10306	Soussi, T., <i>et al.</i> , PCT/FR93/01082	C12N 15/12	C07K 7/08		X
	14.	Mar. 23, 1995	WO 95/07934	Tekamp-Olson, P., <i>et al.</i> , PCT/US94,10356	C07K 16/28	A61K 39/395		X
	15.	Apr. 2, 1998	WO 98/13064	Lu, X., <i>et al.</i> , PCT/GB97/02318	A61K 38/17	38/41		X

## OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)


Examiner Initials	Ref. No.	Title
	16.	Ball, K.L., <i>et al.</i> , "Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21 <sup>WAF1</sup> ", <i>Current Biology</i> , Vol. 7, pp. 71-80, 1996.
	17.	Barak, Y., <i>et al.</i> , "mdm2 expression is induced by wild type p53 activity", <i>The EMBO Journal</i> , Vol. 12, pp. 461-468, 1993.
	18.	Barak, Y., <i>et al.</i> , "Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest", <i>The EMBO Journal</i> , Vol. 11, pp. 2115-2121, 1992.
	19.	Blommers, M.J.J., <i>et al.</i> , "On the Interaction Between p53 and MDM2: Transfer NOE Study of a p53-Derived Peptide Ligated to MDM2", <i>J. Am. Chem. Soc.</i> , Vol. 119, pp. 3425-3426, 1997.
	20.	Böttger, A., <i>et al.</i> , "Molecular Characterization of the hdm2-p53 Interaction", <i>J. Mol. Biol.</i> , Vol. 269, pp. 744-756, 1997.
	21.	Böttger, V., <i>et al.</i> , "Comparative study of the p53-mdm2 and p53-MDMX interfaces", <i>Oncogene</i> , Vol. 18, pp. 189-199, 1999.
	22.	Brown, D.R., <i>et al.</i> , "The Tumor Suppressor p53 and the Oncoprotein Simian Virus 40 T Antigen Bind to Overlapping Domains on the MDM2 Protein", <i>Molecular and Cellular Biology</i> , Vol. 13, pp. 6849-6857, 1993.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).




Form PTO-1449		Attorney's Docket No. 39749-0001APC	Application Serial No. 09/403,440
INFORMATION DISCLOSURE STATEMENT		Applicant(s) David Philip Lane	
(use several sheets if necessary)		Filing Date: January 19, 2000	Group Art Unit: 1642
23.	Cahilly-Snyder, L., et al., "Molecular Analysis and Chromosomal Mapping of Amplified Genes Isolated from a Transformed Mouse 3T3 Cell Line", Somatic Cell and Molecular Genetics, Vol. 13, pp. 235-244, 1987.		
24.	Chen, J., et al., "Mapping of the p53 and mdm-2 Interaction Domains", Molecular and Cellular Biology, Vol. 13, pp. 4107-4114, 1993.		
25.	Chorev, M., et al., "A Dozen Years of Retro-Inverso Peptidomimetics", Acc. Chem. Res., Vol. 26, pp. 266-273, 1993.		
26.	Crystal, R.G., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success", Science, Vol. 270, pp. 404-410, 1995.		
27.	Deffie, A., et al., "The Tumor Suppressor p53 Regulates Its Own Transcription", Molecular and Cellular Biology, Vol. 13, pp. 3415-3423, 1993.		
28.	Derossi, D., et al., "The Third Helix of the Antennapedia Homeodomain Translocates through Biological Membranes", The Journal of Biological Chemistry, Vol. 269, pp. 10444-10450, 1994.		
29.	Dyson, N., et al., "Adenovirus E1A Makes Two Distinct Contacts with the Retinoblastoma Protein", Journal of Virology, Vol. 66, pp. 4606-4611, 1992.		
30.	Dyson, N., et al., "Homologous Sequences in Adenovirus E1A and Human Papillomavirus E7 Proteins Mediate Interaction with the Same Set of Cellular Proteins", Journal of Virology, Vol. 66, pp. 6893-6902, 1992.		
31.	Farmer, G., et al., "Wild-type p53 activates transcription <i>in vitro</i> ", Nature, Vol. 358, pp. 83-86, 1992.		
32.	Funk, W.D., et al., "A Transcriptionally Active DNA-Binding Site for Human p53 Protein Complexes", Molecular and Cellular Biology, Vol. 12, pp. 2866-2871, 1992.		
33.	Gannon, J.V., et al., "Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form", The EMBO Journal, Vol. 9, pp. 1595-1602, 1990.		
34.	Garcia-Echeverria, C., et al., "Structure-Activity Studies of Peptide Inhibitors of the p53-HDM2 Interaction", Oncology Research.		
35.	Kern, S.E., et al., "Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression", Science, Vol. 256, pp. 827-830, 1992.		
36.	Lane, D., "Interruption of binding of MDM-2 and p53 protein; potential for the treatment of cancer", Exp. Opin. Ther. Patents, Vol. 6, pp. 805-809, 1996.		
37.	Lane, D., et al., "On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage", Phil. Trans. R. Soc. Lond., B, Vol. 347, pp. 83-87, 1995.		
38.	Lee, H.S., et al., "Molecular Characterization of <i>nosA</i> , a <i>Pseudomonas stutzeri</i> Gene Encoding an Outer Membrane Protein Required To Make Copper-Containing N <sub>2</sub> O Reductase", Journal of Bacteriology, Vol. 173, pp. 5406-5413, 1991.		
39.	Lees-Miller, S.P., et al., "Human DNA-Activated Protein Kinase Phosphorylates Serines 15 and 37 in the Amino-Terminal Transactivation Domain of Human p53", Molecular and Cellular Biology, Vol. 12, pp. 5041-5049, 1992.		
40.	Lin, J., et al., "Functions of the p53 Protein in Growth Regulation and Tumor Suppression", Cold Spring Harbor Symposia on Quantitative Biology, Vol. LIX, pp. 215-223, 1994.		
41.	Lin, J., et al., "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein", Genes & Development, Vol. 8, pp. 1235-1246, 1994.		
42.	Lin, Y., et al., "Inhibition of Nuclear Translocation of Transcription Factor NF- $\kappa$ B by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence", The Journal of Biological Chemistry, Vol. 270, pp. 14255-14258, 1995.		
43.	Liu, X., et al., "The p53 Activation Domain Binds the TATA Box-Binding Polypeptide in Holo-TFIID, and a Neighboring p53 Domain Inhibits Transcription", Molecular and Cellular Biology, Vol. 13, pp. 3291-3300, 1993.		
44.	Martin, K., et al., "Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein", Nature, Vol. 375, pp. 691-698, 1995.		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).



Form PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b>		Attorney's Docket No. 39749-0001APC	Application Serial No. 09/403,440
		Applicant(s) David Philip Lane	
(use several sheets if necessary)		Filing Date: January 19, 2000	Group Art Unit: 1642
45.	Michalovitz, D., <i>et al.</i> , "Conditional Inhibition of Transformation and of Cell Proliferation by a Temperature-Sensitive Mutant of p53", <i>Cell</i> , Vol. 62, pp. 671-680, 1990.		
46.	Mundt, M., <i>et al.</i> , "The tumor suppressor p53 as a target for tumor therapy: An <i>In vitro</i> transcription system as an indicator of active p53".		
47.	Oliner, J.D., <i>et al.</i> , "Amplification of a gene encoding a p53-associated protein in human sarcomas", <i>Nature</i> , Vol. 358, pp. 80-83, 1992.		
48.	Olson, D.C., <i>et al.</i> , "Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes", <i>Oncogene</i> , Vol. 8, pp. 2353-2360, 1993.		
49.	Orkin, S.H., <i>et al.</i> , "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy", pp. 1-23, 1995.		
50.	Otto, A., <i>et al.</i> , "Upregulation of mdm-2 Expression in Meth A Tumor Cells Tolerating Wild-type p53", <i>Oncogene</i> , Vol. 8, pp. 2591-2603, 1993.		
51.	Phelan, J.C., <i>et al.</i> , "A General Method for Constraining Short Peptides to an $\alpha$ -Helical Conformation", <i>Journal of the American Chemical Society</i> , Vol. 119, pp. 455-460, 1997.		
52.	Picksley, S.M., <i>et al.</i> , "The p53-mdm2 Autoregulatory Feedback Loop: A Paradigm for the Regulation of Growth Control by p53?", <i>BioEssays</i> , Vol. 15, pp. 689-690, 1993.		
53.	Picksley, S.M., <i>et al.</i> , "p53 and Rb: their cellular roles", <i>Current Opinion in Cell Biology</i> , Vol. 6, pp. 853-858, 1994.		
54.	Rojanasakul, Y., "Antisense oligonucleotide therapeutics: drug delivery and targeting", <i>Advanced Drug Delivery Reviews</i> , Vol. 18, pp. 115-131, 1996.		
55.	Schlaeppli, J.M., <i>et al.</i> , "Identification of Specific hdm2 Binding Peptides by Affinity Selection and Mass Spectrometry", <i>Novartis Pharma AG</i> , 1997.		
56.	Schlichtholz, B., <i>et al.</i> , "The Immune Response to p53 in Breast Cancer Patients Is Directed against Immunodominant Epitopes Unrelated to the Mutational Hot Spot", <i>Cancer Research</i> , Vol. 52, pp. 6380-6384, 1992.		
57.	Stephen, C.W., <i>et al.</i> , "Characterisation of Epitopes on Human p53 using Phage-displayed Peptide Libraries: Insights into Antibody-Peptide Interactions", <i>J. Mol. Biol.</i> , Vol. 248, pp. 58-78, 1995.		
58.	Stull, R.A., <i>et al.</i> , "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects", <i>Pharmaceutical Research</i> , Vol. 12, pp. 465-482, 1995.		
59.	Unger, T., <i>et al.</i> , "p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer", <i>The EMBO Journal</i> , Vol. 11, pp. 1383-1390, 1992.		
60.	Wallace, C., "Peptide ligation and semisynthesis", <i>Current Opinion in Biotechnology</i> , Vol. 6, pp. 403-410, 1995.		
61.	Wasylyk, C., <i>et al.</i> , "p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53", <i>Oncogene</i> , Vol. 18, pp. 1921-1934, 1999.		

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	